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Abstract    62 
Background: Weight management including formula total diet replacement is emerging as 63 
effective for severe and complex obesity, particularly with type 2 diabetes (T2DM).  However, 64 
no prospective audit and service evaluation of such programmes are published. 65 
 66 
Methods: Following initial feasibility piloting, the Counterweight-Plus programme was 67 
commissioned across a variety of healthcare providers. The programme includes: Screening, 68 
Total Diet Replacement (formula low energy diet), Food Reintroduction, and Weight Loss 69 
Maintenance, delivered by staff with 8 hours training, in-service mentoring, ongoing specialist 70 
support and access to medical consultant expertise.  Anonymised data are returned centrally for 71 
clinical evaluation.  72 
 73 
Results:  Up to December 2016, 288 patients commenced the programme.  Mean (SD) baseline 74 
characteristics were: age 47.5 years (SD12.7), weight 128.0 kg (SD32.0), BMI 45.7 kg/m2 75 
(SD10.1): 76(26.5%) were male and 99(34.5%) had T2DM.  On an ITT basis, loss of >15kg at 76 
12-months was achieved by 48, representing 22.1% of all who started and 40% of those who 77 
maintained engagement.  For complete cases, mean (95%CI) weight loss(kg) was 78 
13.3(12.1,14.4) at 3-months, 16.0(14.4,17.6) at 6-months and 14.2(12.1,16.3) at 12-months (all 79 
p<0.001), with losses to follow up of 10.8%, 29.3% and 44.2% respectively. Mean loss at 12-80 
months by ITT analyses was: single imputation -10.5kg (9.5), LOCF -10.9kg (11.6) and BOCF -81 
7.9kg (11.1). The presence of diabetes had no significant impact on weight change outcomes.   82 
 83 
Conclusion:  This non-surgical approach is effective for many with severe and complex obesity, 84 
as an option before considering surgery.  The results are equally effective in terms of weight loss 85 
for people with T2DM. 86 
 87 
Key Words 88 
Obesity, weight management, evaluation, behavior change, formula diet. 89 
 90 
 91 
 92 
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Introduction    93 
The rising burden of overweight and obesity on healthcare services, and on personal wellbeing, 94 
is well documented, with many obesity related comorbidities including type 2 diabetes (T2DM), 95 
hypertension, infertility, sleep apnoea, depression, arthritis and various cancers (1,2). The Scottish 96 
Intercollegiate Guidelines Network guidance on the management of obesity recognises a need to 97 
achieve and maintain >15kg (>10%) weight loss with severe and complex obesity (2). This target 98 
is principally justified by the aims of achieving remissions of T2DM initially demonstrated in 99 
patients undergoing bariatric surgery (3) and as demonstrated in the Diabetes Remission Clinical 100 
Trial (DiRECT) randomised controlled trial (4). Greater weight loss is also needed to manage 101 
sleep apnoea and arthritis optimally, and to allow obese patients to benefit from surgical 102 
procedures, for example in gynaecology, fertility services and joint replacement surgery. (5). 103 
  104 
Bariatric surgery is widely recommended in evidence-based guidelines for severe and complex 105 
obesity (usually BMI>40kg/m2 or 35kg/m2 with comorbidities). However, fewer than 1% of 106 
those eligible actually access surgery in most countries (6). As a lower-cost alternative to surgery, 107 
randomised controlled trials using ‘Total Diet Replacement’  low energy formula diets, which 108 
provide 100% of the recommended daily intakes for vitamins and mineralshave shown weight 109 
losses of 10-15kg, maintained for at least 12-months, with striking clinical benefits among 110 
patients with T2DM, sleep apnoea and osteoarthritis(7-9). Total Diet Replacements provide 111 
>800kcal- <1200kcal day and meet nutritional specifications set out in the The Foods Intended 112 
for Use in Energy Restricted Diets for Weight Reduction Regulations 1997 implementing 113 
Commission Directive 96/8 (10). 114 
 115 
The Counterweight Programme initially focused on aiming to establish standard 5-10kg weight 116 
loss methods for service provision within the UK National Health Service. However the mean 117 
BMI of referrals was consistently 37kg/m2, with 25% above 40kg/m2 (11).  Subsequently, with 118 
Scottish Government Health Department funding, Counterweight-Plus was developed and 119 
established to address the ‘intervention gap’ before referral to bariatric surgery, and to satisfy 120 
clinical weight loss targets for people with severe and medically complex obesity (2,12).The 121 
resulting structured, non-surgical programme, aimed at achieving and maintaining >15kg weight 122 
loss for as many patients as possible, has been commissioned by a number of UK NHS and 123 
JHD 9_10_18 
 
5 
 
private health agencies.  Data from all patients are collected centrally for analysis to inform 124 
Continuous Improvement.  Here we document the results from a complete prospective audit over 125 
the 4-year period after  the introduction of Counterweight-Plus, and illustrate how outcomes can 126 
be improved using the principles of Continuous Improvement Methodology (CIM), used since 127 
2001 by Counterweight(11).. 128 
 129 
Methods 130 
This service evaluation adheres to the SQUIRE reporting guidelines (13) 131 
Following the published feasibility study (12) and Continuous Improvement Methodology review, 132 
Counterweight-Plus was made available to public and private healthcare agencies in 2013, 133 
through Counterweight Ltd.  The service is managed by a small central team of registered 134 
healthcare professionals with specialist training in weight management, with access to consultant 135 
physician expertise. 136 
Practitioner Training/Support: In order to be certified to deliver Counterweight-Plus, 137 
practitioners (mainly Registered Dietitians) complete 2 days training from Counterweight 138 
specialists, and a detailed case study. Counterweight Ltd. trainers provide further supervision and 139 
mentoring via email, telephone, webinar and annual study days. Competency is reassessed 140 
annually from practitioner outcomes or completion of a further case study, with further training 141 
and mentoring as necessary. 142 
 143 
Target patient population and referral: The service targets patients requiring weight loss of 144 
the magnitude of around >15kg or>10% for those with a lower baseline weight. For NHS 145 
patients, in areas where funding or part-funding for Counterweight-Plus is available, the service 146 
is provided by dietetic department with referral from clinical specialties where weight loss is 147 
core to the clinical outcome e.g.T2DM care, bariatric surgery etc. Counterweight-Plus can also 148 
be accessed through private health practitioners. On referral, practitioners communicate with 149 
general practitioners (GPs) regarding medical management of the patient, particularly over the 150 
need to review medications for T2DM and hypertension. Standard protocols support this process.  151 
 152 
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Programme structure and Implementation 153 
Screening: Initial screening ensures patients meet the entry criteria of age 18-75, BMI>30kg/m2 154 
or BMI>27kg/m2 plus associated T2DM, appropriate stage of readiness to change based on the 155 
Readiness Ruler (2) and to check for exclusion criteria including active mental illness, myocardial 156 
infarction or stroke within the previous 3 months, severe or unstable heart failure, porphyria, 157 
pregnant until >4 months post-partum; breastfeeding, substance abuse or eating disorder 158 
accompanied by purging.  159 
 160 
The programme stages are detailed in Figure I. Appointments are 60 minutes for the initial 161 
session of the Total Diet Replacement and Food Reintroduction stages, all other appointments 162 
were20 minutes. Counterweight-Plus utilises behaviour change strategies from the CALORE 163 
taxonomy, to support long-term lifestyle modification including barrier identification and 164 
problem solving, goal setting- action planning and review of outcome goals promts (14). Medical 165 
and weight change expectations are also discussed. High-quality patient and practitioner 166 
resources are used throughout the programme.  167 
Total Diet Replacement (TDR):  The phase consisted of 7 appointments over 12-weeks, or up 168 
to 20-weeks if greater weight loss is required, or if ‘diet-holidays’ are taken.  The Total Diet 169 
Replacement product provides 825-853kcal/day from nutritionally complete soups and shakes 170 
plus 50ml low fat milk for teas and coffees.  Macronutrient breakdown is as follows: 61% 171 
carbohydrate, 13% fat and 26% protein. The product used is Counterweight PRO800 (Cambridge 172 
Weight Plan, Corby, England). Sachets comply with specifications for total diet replacement 173 
products (10).  Structured discussions supported by written resources around goal-setting, relapse 174 
management, planning and physical activity starts during TDR. Advice around potential side 175 
effects is discussed and provided in patient materials. Patients are advised to use laxatives with 176 
constipation being a common problem due to the low fibre content of the sachets. 177 
Food Reintroduction (FR): This phase consisted of 6 appointments, re-introducing food-based 178 
meals stepwise over 6-12-weeks to allow flexibility to accommodate individual needs and time-179 
courses for confident transfer onto normal meals. Increased physical activity is advised aiming 180 
for 30 minutes moderate activity per day on at least 5 days per week. Once this is achieved 181 
individuals are advised to aim for 45-60 minutes moderate activity per day (monitoring with 182 
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step-counters or activity trackers if possible) (15). Further nutrition and physical activity 183 
information is provided, encompassing recognised behavioural strategies (14). Orlistat is available 184 
as an option depending on local prescribing access. 185 
Weight Loss Maintenance (WLM): 7 appointments, to consolidate behavioural change 186 
strategies and aim to restrict weight regain to under 2kg at 12-months. A second year of WLM is 187 
also available for commissioning depending on local funding. 188 
Relapse management: If there is weight regain above a pre-defined acceptable level of 2-4kg, a 189 
4-8-week ‘Rescue Plan’ of TDR and/or FR is offered along with a structured weight regain 190 
review and associated materials. 191 
 192 
Medical and Practitioner Support: Any medical queries from practitioners or GPs are 193 
submitted to an experienced consultant weight management physician, using a standard medical 194 
query form. Queries and suggestions from practitioners’ specific to the programme are dealt with 195 
by specialist Counterweight Dietitians. These queries and responses are circulated to all 196 
practitioners as ‘Frequently Asked Questions’ and contribute to CIM.  197 
 198 
Evaluation Methods: Practitioners delivering Counterweight-Plus are given an excel database 199 
to collect standard anonymised data on each patient enrolled into the programme including 200 
reasons for loss to follow up and asked to return the database annually for central 201 
analysis.  Patients are asked to sign a ‘promise agreement’ at the first visit where they commit to 202 
the programme and related sessions and consent is sought for anonymised data being used for 203 
programme evaluation. For patients who had withdrawn from the intervention, data were 204 
collected at 12 months (within a pragmatic ‘window’ of 9-18months), where available, from 205 
measurements recorded at routine medical attendances. 206 
 207 
Statistics: For analysis purposes, and due to the rolling nature of programme enrollment, 208 
predefined rules are applied for eligibility for analysis within time frames and programme stages, 209 
and criteria for loss to follow up. Resulting data are then checked for errors. In addition to 210 
summary statistics and percentages, formal statistical tests included: t-tests, to assess differences 211 
in weight change between groups; univariate and multivariate regressions including sex, diabetes 212 
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status, age and BMI, to estimate the effect of continuous variables on weight change and chi-213 
square tests, to determine the significance of the association between categorical variables. 214 
Bonferroni adjustment of p-values was performed to account for potential type 1 error in 215 
performing repeated t-tests. Twelve-month outcomes are presented for attenders and additional 216 
intention to treat (ITT) analyses used single imputation with 12 month weights from GP records 217 
available for patients withdrawn from the intervention, last observation carried forward and 218 
baseline observation carried forward to allow comparisons with other published studies using 219 
similar methodologies. 220 
 221 
Ethics: the protocol was previously reviewed for the by West of Scotland Research Ethics 222 
Service, which concluded that formal ethical approval was unnecessary, as no new or untested 223 
treatment was being offered, and there was no experimentation (12). This clinical audit of routine 224 
care therefore required formal ethical approval. 225 
 226 
Results 227 
Between January 2013 and December 2016, 288 patients had enrolled in the Counterweight-Plus 228 
programme from nine UK Health Service areas (n=222), one private weight-management service 229 
(n=12) and from 8 individual private freelance Counterweight-Plus trained practitioners (n=54). 230 
Mean(SD) baseline characteristics were: age 47.5 years (SD12.7), weight 128.0 kg (SD32.0) and 231 
BMI 45.7 kg/m2 (SD10.1), 76(26.5) % were male and 99(34.5) % had diabetes (97% T2DM) 232 
(Table I). At the time of analysis 277, 246 and 217 patients were potentially eligible for 3, 6 and 233 
12month weight change analysis respectively, due to the rolling entry into audit.   The numbers 234 
of eligible patients who attended at these time-points were 247(89%), 174(71%) and 121(56%).  235 
In those attending at 12 months, mean number of appointments was 16 (SD4.4). 236 
 237 
Data were obtained from GP records for 19 patients who had ceased to attend, showing mean 238 
(SD) loss of 6.0 kg (SD8.5) at 12 months. 239 
 240 
Mean(SD) weight-losses (kg) in attenders were 12.7(SD8.0), 15.8(SD9.9) and 14.2(SD11.6), at 241 
3, 6 and 12-months respectively. Mean loss at 12-months by ITT analyses was: single imputation 242 
-10.5kg (9.5), LOCF -10.9kg (11.6) and BOCF -7.9kg (11.1). 243 
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 244 
The target weight loss of 15kg at 12-months was achieved by 22%, and >10% loss by 28%, of all 245 
patients entering the programme. Among the 56% who continued engagement up to 12-months, 246 
40% maintained a weight loss of >15kg, with mean loss of 14.2kg. In addition to the 15kg target, 247 
clinically beneficial weight loss of >5kg was achieved at 3, 6 and 12months by 216(78%), 248 
161(65.4%) and 96(44.2%) respectively on an ITT basis. Summary weight changes are given in 249 
Table II showing follow up and mean loss for attenders and by ITT (single imputation, BOCF 250 
and LOCF) at each time point and numbers (%) achieving the defined categories of weight 251 
change. Figure II illustrates the proportion of attenders in each weight-loss category and lost to 252 
follow up for each data time point. 253 
 254 
Table III outlines through multi-variate regressions that baseline BMI and sex had a significant 255 
impact on weight-change at each time point: on average males, and those with higher BMI at 256 
baseline, lost more weight. The presence of diabetes and age had no significant impact. 257 
 258 
Weight-loss at 12-months was positively related to weight-change that had been achieved at 3 259 
and 6-months. For every 1-kg greater weight-loss at 3 and 6-months, weight loss at 12-months 260 
was greater by 0.9kg (95% CI 0.72,1.11) and 1.1kg (95% CI 0.98,1.18) respectively. 261 
 262 
Later entry to the programme, over the 4-year observation period, was significantly related to 263 
better 12-month retention: 73.8% for those starting after the mid-point (March 2014 – December 264 
2016), as compared to 52.6% in those starting prior to the midpoint of recruitment (January 2013 265 
– March 2014) (p<0.01).  266 
 267 
For relapse management, brief ‘rescue plans’ were given to 30 of the 217 patients eligible for 12-268 
month follow up (14%).   269 
 270 
Longer support beyond 12-months has been offered by some practitioners, and follow-up data at 271 
24-months were available for 46 (35%) of 131 who had started more than 2-years prior to the 272 
audit date. Their mean loss at 24-months was 13.5 kg (SD14.8) with 39% maintaining the target 273 
loss of >15kg. 274 
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Discussion 275 
No previous published evaluation has examined a TDR method outside of a specialist centre 276 
setting or clinical trial.  Our audit and service evaluation has presented data on all 288 obese 277 
patients who entered a structured non-surgical intensive weight-management programme. 278 
Patients enrolled had severe and complex obesity at baseline: mean BMI was 46kg/m2 and 34% 279 
had T2DM. This severity and complexity of obesity requires greater weight loss than 280 
conventional ‘lifestyle only’ programmes can achieve, hence there is need for a non-surgical 281 
intensive intervention because access to bariatric surgery is limited globally and also holds low 282 
appeal for large numbers (16). 283 
 284 
The Counterweight-Plus programme achieved weight loss of 14.2kg at 12 months in the 285 
attending population reflecting considerably greater maintained weight-loss than is reported with 286 
conventional diet and lifestyle interventions, with no worse adherence to this more intensive 287 
programme(11).  288 
In this evaluation, baseline characteristics associated with greater 12-month weight-loss included 289 
higher baseline BMI and being male. It is notable that the men achieved greater weight-losses, 290 
mean 18.8kg even though 58% of men had diabetes, and the results were equally good for people 291 
with diabetes contrary to previous published work in weight management (17). Evidence is 292 
accumulating that with weight loss of the order of 15kg, remission of T2DM may be possible for 293 
large numbers, bringing major personal, social and medical benefits as well as avoiding the costs 294 
of medications prescribed to people with T2DM.  Lim et al. showed that remission of T2DM 295 
resulted from weight loss c.15kg, using 8 weeks TDR, with loss of the ectopic fat in liver and 296 
pancreas, and restoration of first-phase insulin release(8). The DiRECT randomised controlled 297 
trial (RCT) published 12-month outcomes showing T2DM remission rates of 86% with weight 298 
loss of >15kg and 73% with weight loss of >10kg using Counterweight-Plus(4). 299 
 300 
Outcomes for Counterweight-Plus at 12-months in our service evaluation are reassuringly similar 301 
to many published high quality RCTs of formula diet interventions(18).  There are no directly 302 
comparable routine-service evaluations however published outcomes are available from an 303 
Australian specialist tertiary hospital multidisciplinary weight management clinic which used an 304 
initial full or partial very-low-energy diet (550 kcal/day VLED) with monthly/bimonthly 305 
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attendance, followed by stepped food reintroduction and weight loss maintenance review every 306 
1-3 months (19). Despite the specialist multi-disciplinary support, 12-month outcomes were better 307 
for Counterweight-Plus both in terms of attenders weight change: 12.7kg vs 9.7kg and loss to 308 
follow up; 44% vs 58%  309 
 310 
The present data add to growing evidence that greater, more rapid, early weight-loss leads to 311 
better longer-term outcomes.  Weight-loss at 3 and 6-months were positively correlated with 312 
outcomes at 12-months. This counters the widespread belief that rapid initial early weight-loss is 313 
quickly regained on reverting to a food-based diet(20).The TDR approach was favourably 314 
received by patients.  Programme retention was exceptionally high during TDR at 89%: 315 
motivation is high when weight loss is rapid (20). The complete step away from usual food and 316 
drink allows the opportunity to re-educate and consolidate long-term plans for food choice and 317 
weight control, using a range of behavior-change strategies, delivered by a trained health 318 
professional. 319 
 320 
Loss to follow up is a common problem with weight management and other lifestyle 321 
interventions(21). The use of formula diet in RCT studies have shown retention of rates of 17-21% 322 
(22,4) In one, study participants were seen weekly and given ongoing free of charge formula 323 
product as part of the weight loss maintenance intervention (22) but this high level of retention 324 
may also reflect the population recruited being committed to the research being carried out. 325 
However in otherRCTs where patients have volunteered to be part of a scientific study, often 326 
with incentives, 12-month loss to follow up is commonly over 40% (23), similar to that seen in the 327 
present service evaluation. In non RCT interventions a specialist UK service including 328 
psychology, dietetics and exercise therapists, published an 80% loss to follow up at 12-months(24)  329 
The results for the Counterweight-Plus service evaluation showed reduced loss to follow up, and 330 
also better weight-loss outcomes, for patients who started the programme after the 2-year 331 
midpoint date of the 4-year period for enrollment reported here. This improvement may partly 332 
represent the success of the Continuous Improvement Methodology integral to Counterweight-333 
Plus, whereby practitioners report problems and ideas for programme refinements, and ongoing 334 
central review of the results identifies areas for further training or greater support. However, 335 
increased confidence and experience of practitioners would also contribute to the improved 336 
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outcomes. Sensitivity analysis on imputed data showed greater weight loss in attenders than 337 
those who did not attend (LOCF:10.9kg; BOCF 7.9kg) however we do not have information on 338 
those failed to attend at the 12-month point and therefore what their weight change would be. 339 
While outcomes on attender cases may overestimate the effect of the programme this conclusion 340 
could only be confirmed with actual weight change data for those not attending. 341 
 342 
As with all weight management studies, there was some regain from the greatest mean weight-343 
loss of 15.8kg at 6-months, to 14.2kg at 12-months.  Rescue plans had been given to 30 of the 344 
217 patients eligible for 12-month follow up (14%). Weight loss at 12-months was no worse for 345 
those receiving rescue plans, so this measure was having the intended effect. The data indicate 346 
no major rebound weight regain, with mean regain of 1.6kg (10% of total weight loss) between 6 347 
and 12-months. Our limited 24-month data suggest that an important proportion already maintain 348 
their weight loss in the longer term.  349 
 350 
The main limitations of this service evaluation lie in access around wider data of interest such as 351 
details of changes in related clinical conditions such as T2D, recorded information around side 352 
effects such as constipation and outcomes for patients who withdraw from the intervention. 353 
Improved resource would be needed to address this coupled with systems to automatically access 354 
associated patient outcomes and prescribing data such as information on the use of orlistat. 355 
Feedback from practitioners suggested very low uptake of orlistat as an option, however without 356 
specific details on this the potential influence on weight change should not be discounted. A 357 
further limitation is that the focus is on 12-month outcomes however this again is largely driven 358 
by the available resource within routine NHS weight management. Finally, there may be 359 
recruitment bias and a control arm would add to the conclusions drawn.  360 
 361 
In summary, Counterweight-Plus provides a practical option for patients who need to lose more 362 
weight than is achieved through conventional lifestyle interventions, but for whom bariatric 363 
surgery is unavailable or unacceptable.  Unlike many treatments the results are equally good for 364 
people with diabetes. Outcomes compare favourably with the DiRECT RCT despite a more 365 
medically complex group and non RCT delivery and support structure.Using Continuous 366 
Improvement Methods, the programme has been enhanced by providing greater flexibility, 367 
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which has improved acceptability and in turn improved retention and weight loss. Further 368 
improvements to the programme include offering longer-term support for weight loss 369 
maintenance with dynamic approaches for prevention of weight regain as well as development of 370 
a digital option. Future research to improve longer term weight loss maintenance is warranted, 371 
and more high-quality audits of real-life management in routine services should be published (25).  372 
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Figure I: Programme Structure 485 
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Table I: Baseline Characteristics  509 
Baseline Characteristic Service Evaluation Population: 
Counterweight-Plus 
Total number patients 288 
Mean age (years) (sd) 47.5 (12.7) 
% males 26.5 
Mean BMI (kg/m2) (sd) 45.7 (10.1) 
% with Type 2 diabetes 34.4 
 510 
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Table II: Summary weight change data for 277 patients managed through Counterweight-536 
Plus and eligible for 3-month follow up and beyond.   537 
Data are shown for (a) ‘Attenders’ who remained engaged in the programme at each time-point; 538 
(b) ITT Single Imputation (b) ITT (Last Observation Carried Forward) and (c) ITT (Baseline 539 
Observation Carried Forward).  540 
 3 months 6 months 12 months 24 months 
a) Attenders     
n eligible 277 246 217* 46** 
n (%) with data 247(89) 174 121 46 
Mean Weight 
Change(SD) -12.7 (8.0) -15.8 (9.9) -14.2 (11.6) -13.5 (14.8) 
*P value*** <0.01 <0.01 <0.01 <0.01 
 
b)ITT (imputed 
weight change -
6.0kg) na na -10.5 (9.5) na 
 
bc)ITT (LOCF) na na -10.9 (11.6) na 
cd) ITT (BOCF) na na -7.9 (11.1) na 
    
Weight change categories, n(%)    
Weight gain 3 (1.1) 3 (1.2) 3 (1.4) 9(19.6) 
0 < 5kg loss 28 (10.1) 10 (4.1) 22 (10.1) 4(8.7) 
5kg+loss 216 (78.0) 161 (65.4) 96 (44.2) 33(71) 
10kg+loss 150 (54.2) 120 (48.7) 69 (31.8) 26(57) 
15kg+loss 82 (29.6) 83 (33.7) 48 (22.1) 18(39) 
LTFU**** 30 (10.8) 72 (29.3) 96 (44.2) na** 
 541 
*the rolling nature of programme recruitment resulted in fewer people being eligible for the latter 542 
data capture time points 543 
**because 24m follow up is not routinely provided at this stage so only those followed up at 24m 544 
are eligible 545 
***P<0.01 for both one-sample t-test and Wilcoxon signed-rank test at all time points. Weight 546 
change at 3m compared to baseline was analysed using 1-sample t-test, with null hypothesis of H0: 547 
weight change at 3m = 0.  This is equivalent to a paired t-test comparing weight at 3m vs baseline, testing 548 
the null hypothesis of H0: weight at 3m = weight at baseline. This test was repeated for 6m and 12m 549 
compared to baseline.   Bonferroni adjustment had no effect on the significance of the p-values. 550 
****Loss to Follow Up 551 
 552 
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Table III: Multi-variate regressions of weight change at 3m, 6m, 12m by BMI, age, diabetes 553 
and sex at baseline 554 
 555 
Variable Wtloss       
  Coef (95%CI) P-value F-value R-squared 
3 months    
4.3 0.1396 
BMI 0.17 (0.07, 0.27) <0.01     
Age 0.00 (-0.08, 0.09) 0.95     
Diabetes -1.82 (-4.02, 0.37) 0.10     
Male 6.16 (3.80, 8.51) <0.01     
6 months    
7.11 0.1594 
BMI 0.28 (0.12, 0.43) <0.01     
Age 0.02 (-0.11, 0.15) 0.78     
Diabetes -3.04 (-6.35, 0.27) 0.07     
Male 6.96 (3.42, 10.51) <0.01     
12 months    
4.3 0.1396 
BMI 0.29 (0.07, 0.51) 0.01     
Age -0.01 (-0.19, 0.17) 0.88     
Diabetes -2.46 (-7.01, 2.08) 0.29     
Male 7.44 (2.74, 12.15) <0.01     
 556 
 557 
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 559 
 560 
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